VAQTA showed sustained immunogenicity for at least 6 years in adult patients

VAQTA is indicated for the prevention of disease caused by hepatitis A virus (HAV) in persons 12 months of age and older. The primary dose should be given at least 2 weeks prior to expected exposure to HAV.

Adult – Immunogenicity

AT 6 YEARS

VAQTA showed sustained immunogenicity for at least 6 years in adult patients

VAQTA showed sustained immunogenicity for at least 6 years in adult patients

In a clinical study of adult subjects who received 2 doses of VAQTA 6 months aparta:

99.4%

SEROCONVERSION RATES
AFTER 6 YEARS

(n=171)

a In a clinical study that evaluated adults who received VAQTA at 0 and 6 months, 99.4% (170/171) of subjects still had detectable levels of anti-hepatitis antibodies 6 years later.

 Six years postvaccination, patients had a GMT of 684 mIU/mL.

 Anti-HAV antibodies ≥10 mIU/mL indicate seroconversion.

 The total duration of the protective effect of VAQTA in healthy vaccinees is unknown at present.

VAQTA® (Hepatitis A Vaccine, Inactivated) Showed Sustained Immunogenicity For at Least 6 Years in Adult Patients
Not Actual Patient
VAQTA® (Hepatitis A Vaccine, Inactivated) Showed Sustained Immunogenicity For at Least 6 Years in Adult Patients
Not Actual Patient

aIn a clinical study that evaluated adults who received VAQTA at 0 and 6 months, 99.4% (170/171) of subjects still had detectable levels of anti-hepatitis antibodies 6 years later.

Six years postvaccination, patients had a GMT of 684 mIU/mL.

Anti-HAV antibodies ≥10 mIU/mL indicate seroconversion.

The total duration of the protective effect of VAQTA in healthy vaccinees is unknown at present.

Indication for VAQTA

VAQTA® (Hepatitis A Vaccine, Inactivated) is indicated for the prevention of disease caused by hepatitis A virus (HAV) in persons 12 months of age and older. The primary dose should be given at least 2 weeks prior to expected exposure to HAV.

Dosage and Administration for VAQTA

Adults (19 years of age and older): The vaccination schedule consists of a primary 1 mL dose administered intramuscularly and a 1 mL booster dose administered intramuscularly 6 to 18 months later.

Booster Immunization Following Another Manufacturer's Hepatitis A Vaccine: A booster dose of VAQTA may be given at 6 to 12 months following a primary dose of Havrix*.

*Havrix is a registered trademark of GlaxoSmithKline.

Do not administer VAQTA to individuals with a history of immediate and/or severe allergic or hypersensitivity reactions (eg, anaphylaxis) after a previous dose of any hepatitis A vaccine, or to individuals who have had an anaphylactic reaction to any component of VAQTA, including neomycin.

Do not administer VAQTA® (Hepatitis A Vaccine, Inactivated) to individuals with a history of immediate and/or severe allergic or hypersensitivity reactions (eg, anaphylaxis) after a previous dose of any hepatitis A vaccine, or to individuals who have had an anaphylactic reaction to any component of VAQTA, including neomycin.

The vial stopper and the syringe plunger stopper and tip cap contain dry natural latex rubber that may cause allergic reactions in latex-sensitive individuals.

The most common local adverse reactions and systemic adverse events (≥15%) reported in different clinical trials across different age groups when VAQTA was administered alone or concomitantly were:

  • Adults 19 years of age and older: injection-site pain, tenderness, or soreness (67.0%), injection site warmth (18.2%), and headache (16.1%).

Safety and effectiveness in infants below 12 months of age have not been established.

Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished immune response to VAQTA and may not be protected against HAV infection after vaccination.

Hepatitis A virus has a relatively long incubation period (approximately 20 to 50 days). VAQTA may not prevent hepatitis A infection in individuals who have an unrecognized hepatitis A infection at the time of vaccination.

In clinical trials in children, VAQTA was concomitantly administered with one or more of the following US-licensed vaccines: Measles, Mumps, and Rubella Virus Vaccine, Live; Varicella Vaccine, Live; Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine, Adsorbed; Measles, Mumps, Rubella, and Varicella Vaccine, Live; Pneumococcal 7-valent Conjugate Vaccine; and Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate). Safety and immunogenicity were similar for concomitantly administered vaccines compared to separately administered vaccines.

The total duration of the protective effect of VAQTA in healthy vaccinees is unknown at present.

Vaccination with VAQTA may not result in a protective response in all susceptible vaccinees.

Before administering VAQTA, please read the accompanying Prescribing Information. The Patient Information also is available.

VAQTA® (Hepatitis A Vaccine, Inactivated) is indicated for the prevention of disease caused by hepatitis A virus (HAV) in persons 12 months of age and older. The primary dose should be given at least 2 weeks prior to expected exposure to HAV.

Dosage and Administration for VAQTA

Adults (19 years of age and older): The vaccination schedule consists of a primary 1 mL dose administered intramuscularly and a 1 mL booster dose administered intramuscularly 6 to 18 months later.

Booster Immunization Following Another Manufacturer's Hepatitis A Vaccine: A booster dose of VAQTA may be given at 6 to 12 months following a primary dose of Havrix*.

*Havrix is a registered trademark of GlaxoSmithKline.

vaxRef

You are about to leave MerckVaccines.com

Vaxelis

Thank you for visiting.


US-VAQ-00504 02/21